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Background: Single-nucleotide polymorphisms (SNPs) around the apolipoprotein A5 gene (APOA5) have
pleiotropic effects on the levels of triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C). APOA5 SNPs
have also been associated with metabolic syndrome (MS). Here, we constructed haplotypes with SNPs spanning
APOA5 and ZNF259, which are approximately 1.3 kb apart, to perform association analyses with the risk for MS and
the levels of TG and HDL-C in terms of a TG:HDL-C ratio.
Methods: The effects of three constructed haplotypes (TAA, CGG, and CGA, in the order of rs662799, rs651821, and
rs6589566) on the TG:HDL-C ratio and MS were estimated using multiple regression analyses in 2,949 Koreans and
in each gender separately (1,082 men and 1,867 women).
Results: The haplotypes, CGG and CGA, were associated with the TG:HDL-C ratio and the risk of MS development
in both genders. That is, the minor alleles of the rs662799 and rs651821 in APOA5, irrespective of which allele was
present at rs6589566, had the marked effects. Interestingly, a C–G–A haplotype at these three SNPs had the most
marked effects on the TG:HDL-C ratio and the risk of MS development in women.
Conclusions: We have identified the novel APOA5-ZNF259 haplotype manifesting sex-dependent effects on elevation
of the TG:HDL-C ratio as well as the increased risk for MS.
Keywords: APOA5, ZNF259, Haplotype, Triglceride-to-HDL cholesterol ratio, Triglyceride, HDL cholesterol, Metabolic
syndrome, PolymorphismIntroduction
Single-nucleotide polymorphisms (SNPs) in the apolipo-
protein A5 gene (APOA5), located on chromosome 11q23
near the APOA1–C3–A4 gene cluster, have pleiotropic ef-
fects on changes in the levels of triglycerides (TG) and
high-density lipoprotein cholesterol (HDL-C) [1,2]. Re-
cently, a genome-wide association study (GWAS) reported
that the minor allele of a SNP, rs964184, has a bivariate ef-
fect on TG-elevation and HDL-C-decrease [3]. These* Correspondence: scha@kiom.re.kr; ksong@kiom.re.kr
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unless otherwise stated.pleiotropic bivariate associations of APOA5 SNPs, in turn,
affect the risk for metabolic syndrome (MS) [1,2,4].
Haplotype analyses of association of APOA5 SNPs
with lipid levels and risk for MS have focused primarily
on variants located within APOA5 or within the APOA1–
C3–A4–A5 gene cluster [5-12]. In particular, the APOA5
haplotypes, APOA5*1, and *2, and *3, comprised of
rs662799 (−1131T>C), rs3135506 (56C>G), rs2072560
(IVS3 + 476G>A), and rs2266788 (1259T>C), have been
studied for association with lipid levels and MS [5,11-13].
The APOA5*2 haplotype, determined by the minor alleles
of rs662799, rs2072560, and rs2266788, has been associ-
ated with elevated TG levels and risk for the development
of MS [11-13], while the APOA5*3 haplotype, determined. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ciate with increased levels of TG [4,5].
However, APOA5 is adjacent to the zinc finger protein
259 gene (ZNF259; approximately 1.3 kb downstream of
APOA5), so that separation of the effects of these closely
located genes is difficult. In fact, it is possible that
crosstalk between APOA5 and ZNF259 contributes to
modulation of plasma TG levels. Although the precise
mechanisms associated with this have yet to be deter-
mined, research has indicated that APOA5 interaction
with proteoglycan-bound lipoprotein lipase and with
low-density lipoprotein receptor can reduce plasma TG
levels by hydrolysis of TG-rich lipoproteins and by
endocytosis of remnant lipoproteins, respectively [14].
ZNF259 encodes a zinc finger protein ZPR1 that binds
to the cytoplasmic tyrosine kinase domain of epidermal
growth factor receptor (EGFR) in quiescent cells [15].
When mitogens such as EGF disrupt ZPR1 binding by
tyrosine phosphorylation of EGFR, ZPR1 is translocated
to the nucleus. It has been reported that remnant lipo-
proteins, among TG-rich lipoproteins, induce EGFR
phosphorylation in smooth muscle cells, which results in
smooth muscle cell proliferation and atherosclerosis risk
[16] and that EGF concentrations in plasma and periph-
eral blood mononuclear cells associate with lipid concen-
trations, including TG and HDL-C [17]. Furthermore, the
variants exerting effects on TG and HDL-C levels, includ-
ing rs662799, rs3135506, rs651821, rs2072560, rs2266788,
rs6589566, and rs964184, cluster together and are in
strong linkage disequilibrium (LD) with each other around
the two genes [3,18,19]. Therefore, construction of haplo-
types with variants spanning both genes is necessary to es-
timate the precise TG-elevating and HDL-C-lowering
effects of APOA5 SNPs in a population.
The current study aimed to determine the effects of
haplotypes constructed from variants located aroundTable 1 Characteristics of recruited subjects
Characteristic All (n = 2,949) Men (n
Age (y) 48.20 ± 15.73 47.87 ± 1
BMI (kg/m2) 23.50 ± 3.339 24.06 ± 3
WC (cm) 84.19 ± 9.890 87.20 ± 8
SBP (mmHg) 119.9 ± 15.72 123.3 ± 1
DBP (mmHg) 77.12 ± 11.26 79.38 ± 1
FBG (mg/dL) 98.91 ± 28.24 102.2 ± 2
TG (mg/dL) 126.8 ± 82.83 148.1 ± 9
HDL-C (mg/dL) 47.16 ± 12.35 42.58 ± 1
Log[TG]:HDL-C 0.04672 ± 0.01553 0.05303
MS (%) 32.18 33.46
Values are indicated as mean ± standard deviation.
Abbreviations: BMI body mass index, WC waist circumference, SBP systolic blood pre
HDL-C high-density lipoprotein cholesterol, Log[TG]:HDL-C log-transformed TG:HDL-
*Wilcoxon rank sum test except chi-squared test for MS.APOA5 and ZNF259 on the levels of TG and HDL-C, in
terms of a ratio of TG to HDL-C, as well as on the risk
for MS development. Due to the stronger effects of TG
levels on risk of coronary disease in the context of HDL-
C levels [20] and the high correlation between the levels
of TG and HDL-C, the TG:HDL-C ratio can be a more
efficient predictor of the risk for coronary artery diseases
[21,22]. In addition, sex-dependent association patterns
of these haplotypes were evaluated due to the reported
gender effect of APOA5 haplotypes on MS risk [11].
Results
Characteristics of recruited subjects and constructed
haplotypes
Characteristics of the recruited subjects are presented in
Table 1 and Additional file 1. Age and the prevalence of
MS between men and women, as well as the gender pro-
portion according to MS status, were not statistically
different, unlike other clinical characteristics. As the linkage
of rs6589566 (A>G) with rs662799 (−1131T>C; r2 = 0.60)
and rs651821 (−3A>G; r2 = 0.56) in the studied population
was weaker than that in the Asian HapMap population
(both r2= 0.80), three rather than two APOA5–ZNF259
haplotypes with an allele frequency > 5% were constructed,
such that TAA (ht1: 68.9%), CGG (ht2: 20.4%), and CGA
(ht3: 8.57%) in the order of rs662799, rs651821, and
rs6589566 (Figure 1). The genotypes of the three SNPs did
not deviate from Hardy–Weinberg equilibrium (p > 0.05).
Therefore, the genetic effects of these three haplotypes on a
ratio of log[TG] (log-transformed TG): HDL-C and MS
risk were evaluated in Koreans.
Associations of APOA5-ZNF259 haplotypes with TG:HDL-C
ratio and MS risk
Carriage of haplotypes ht2 or ht3, versus the ht1 haplo-
type, was significantly associated with increased levels of= 1,082) Women (n = 1,867) P*
5.84 48.39 ± 15.66 0.628
.219 23.17 ± 3.364 <0.0001
.867 82.45 ± 10.03 <0.0001
4.86 117.9 ± 15.88 <0.0001
1.08 75.80 ± 11.16 <0.0001
9.92 97.00 ± 27.05 <0.0001
5.48 114.4 ± 71.70 <0.0001
0.81 49.81 ± 12.41 <0.0001
± 0.01622 0.04306 ± 0.01386 <0.0001
31.44 0.276
ssure, DBP diastolic blood pressure, FBG fasting blood glucose, TG triglyceride,
C ratio, MS metabolic syndrome.
Figure 1 Genetic location, linkage disequilibrium (LD), and haplotypes of single-nucleotide polymorphisms (SNPs). (A) The SNPs
rs662799 and rs651821 are respectively located in the promoter and 5′ untranslated regions of APOA5 that has 4 exons, whereas SNP rs6589566 is
found in intron 12 of ZNF259 that has 14 exons. (B) LD structure of three SNPs: D′ and r2. (C) Haplotype sequence and frequency: haplotypes
with frequencies over 5% were named as ht1, ht2, and ht3.
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0.00222, 95% CI = 0.00130 - 0.00315; for ht3 vs ht1, ef-
fect = 0.00460, 95% CI = 0.00313 - 0.00607), whereas car-
riage of the ht3 haplotype versus the ht2 haplotype
showed only a tendency toward elevating the log[TG]:
HDL-C ratio (Table 2). When the population was strati-
fied by gender, the genetic effects of the two haplotypes,
ht2 and ht3, versus ht1 haplotype on log[TG]:HDL-C ra-
tio remained significant, in both genders (for ht2 vs ht1:
effect = 0.00328, 95% CI = 0.00154 - 0.00502, in men and
effect = 0.00157, 95% CI = 0.00507 - 0.00264 in women;
for ht3 vs ht1: effect = 0.00606, 95% CI = 0.00324 -
0.00888 in men and effect = 0.00391, 95% CI = 0.00223 -
0.00558 in women). Interestingly, haplotype ht3, with
reference to haplotype ht2, was significantly associated
with elevation of the log[TG]:HDL-C ratio only inwomen (effect = 0.00473, 95% CI = 0.00130 - 0.00816).
Therefore, the ht3 haplotype showed a sex-dependent as-
sociation with the log[TG]:HDL-C ratio.
The sex-dependent association of the haplotype ht3
was more marked in analyses of the risk of MS (Table 3).
The genetic effect of the ht2 haplotype versus the ht1
haplotype on an increased risk for MS remained signifi-
cant in men (odds ratio (OR) = 1.50, 95% CI = 1.16 –
1.94), while the effect of ht3 haplotype versus ht1
haplotype remained significant in women (OR = 1.41,
95% CI = 1.00 – 1.97). Moreover, association of the ht3
haplotype versus the ht2 haplotype was significant only
in women (OR = 2.67, 95% CI = 1.25 – 6.07). Taken to-
gether, unlike men, women harboring the ht3 haplotype
were the most susceptible to MS risk and elevation of
the log[TG]:HDL-C.
Table 2 Association of haplotypes in APOA5 and ZNF259 gene regions with log[TG]:HDL-C ratio
Subject Hap 1 & 2 11/12/22 [n] 11/12/22 [mean (sd)] Effect (95% CI)* P*
All ht1, ht2 1,398/838/115 0.0448 (0.0145)/0.0471 (0.0155)/0.0509 (0.0165) 0.00222 (0.00130 - 0.00315) 2.68E-06
ht1, ht3 1,398/340/17 0.0448 (0.0145)/0.0491 (0.0173)/0.0587 (0.0154) 0.00460 (0.00313 - 0.00607) 1.05E-09
ht2, ht3 115/123/17 0.0509 (0.0165)/0.0537 (0.0180)/0.0587 (0.0154) 0.00289 (−0.000221 - 0.00599) 0.0686
Men ht1, ht2 482/325/42 0.0508 (0.0155)/0.0528 (0.0156)/0.0609 (0.0159) 0.00328 (0.00154 - 0.00502) 2.25E-04
ht1, ht3 482/124/5 0.0508 (0.0155)/0.0567 (0.0176)/0.0590 (0.0125) 0.00606 (0.00324 - 0.00888) 2.83E-05
ht2, ht3 42/54/5 0.0609 (0.0159)/0.0605 (0.0194)/0.0590 (0.0125) 0.00122 (−0.00486 - 0.00731) 0.690
Women ht1, ht2 916/513/73 0.0417 (0.0128)/0.0435 (0.0143)/0.0452 (0.0140) 0.00157 (0.000507 - 0.00264) 3.84E-03
ht1, ht3 916/216/12 0.0417 (0.0128)/0.0447 (0.0156)/0.0585 (0.0170) 0.00391 (0.00223 - 0.00558) 5.20E-06
ht2, ht3 73/69/12 0.0452 (0.0140)/0.0484 (0.0150)/0.0585 (0.0170) 0.00473 (0.00130 - 0.00816) 7.16E-03
*The effect (beta), 95% confidence interval (CI), and p-value for Hap 2 versus Hap 1 were estimated by linear regression, after adjusting for age, sex (in all
subjects), physical activity (three categories), daily food intake (three categories), clinical history, and medications for hypertension, dyslipidemia, and/or diabetes.
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Recent GWAS findings indicated that genes with vari-
ants influencing MS per se included the APOA5,
ZNF259, and BUD13 homolog); these genes are known
to play an important role in lipid metabolism [2]. We
also recently reported that the APOA5 − 1131T>C poly-
morphism (rs662799) is associated with the risk of MS
because of its marked effect on serum TG and HDL-C
levels in Korean subjects [1]. The current study hasTable 3 Association of haplotypes in APOA5 and ZNF259 gene
Subject Hap 1 & 2 Subgroup* 11/12/2
All ht1, ht2 Control 988 (61.3
Case 410 (55.5
ht1, ht3 Control 988 (80.8
Case 410 (77.1
ht2, ht3 Control 66 (45.5)
Case 49 (44.5)
Men ht1, ht2 Control 336 (58.9
Case 146 (52.3
ht1, ht3 Control 336 (80.2
Case 146 (76.0
ht2, ht3 Control 19 (34.5)
Case 23 (50.0)
Women ht1, ht2 Control 652 (62.6
Case 264 (57.4
ht1, ht3 Control 652 (81.1
Case 264 (77.6
ht2, ht3 Control 47 (52.2)
Case 26 (40.6)
*Control: subjects with <3 MS risk factors ((1) abdominal obesity with waist circumf
130 mmHg, diastolic blood pressure ≥ 85 mmHg, or medication for hypertension, (3
and (5) fasting blood glucose ≥ 110 mg/dL or medication for hyperglycemia); case:
†The odds ratio (OR), 95% confidence interval (CI), and p-value for Hap 2 versus Hap
subjects), physical activity (three categories), daily food intake (three categories), cliafresh identified that haplotype constructed by SNPs in
the closely positioned APOA5–ZNF259 gene region was
sex-dependently associated with the ratio of TG to
HDL-C and the risk of MS development in Koreans.
Specifically, haplotype ht3, viz., C–G–A at rs662799,
rs651821, and rs6589566, respectively, was most signifi-
cantly associated with elevation of the log[TG]:HDL-C
ratio, as well as MS susceptibility, in women. We suggest
that a causal variant in LD with this APOA5–ZNF259regions with metabolic syndrome (MS) risk
2 [n (%)] OR (95% CI)† P†
)/558 (34.6)/66 (4.09) 1
)/280 (37.9)/49 (6.63) 1.33 (1.13 - 1.57) 0.000529
)/229 (18.7)/6 (0.491) 1
)/111 (20.9)/11 (2.07) 1.41 (1.09 - 1.82) 0.00906
/73 (50.3)/6 (4.14) 1
/50 (45.5)/11 (10.0) 1.31 (0.799 - 2.17) 0.285
)/215 (37.7)/19 (3.33) 1
)/110 (39.4)/23 (8.24) 1.50 (1.16 - 1.94) 0.00197
)/81 (19.3)/2 (0.477) 1
)/43 (22.4)/3 (1.56) 1.43 (0.950 - 2.14) 0.0842
/34 (61.8)/2 (3.64) 1
/20 (43.5)/3 (6.52) 0.766 (0.356 - 1.63) 0.489
)/343 (32.9)/47 (4.51) 1
)/170 (37.0)/26 (5.65) 1.21 (0.976 - 1.50) 0.0813
)/148 (18.4)/4 (0.498) 1
)/68 (20.0)/8 (2.35) 1.41 (1.00 - 1.97) 0.0463
/39 (43.3)/4 (4.44) 1
/30 (46.9)/8 (12.5) 2.67 (1.25 - 6.07) 0.0142
erence ≥ 90 cm for men and ≥ 80 cm for women, (2) systolic blood pressure ≥
) TG ≥ 150 mg/dL, (4) HDL-C < 40 mg/dL for men and < 50 mg/dL for women,
subjects with ≥3 MS risk factors.
1 were estimated by logistic regression, after adjusting for age, sex (in all
nical history, and medications for hypertension, dyslipidemia, and/or diabetes.
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and thus contribute to the risk of MS and coronary ar-
tery disease.
In terms of sex-specific influences of the APOA5–
ZNF259 haplotype on the TG:HDL-C ratio and MS risk,
rs6589566, which is located in the ZNF256 intron, will
have an important role only in women, such that the
major allele of the ZNF256 SNP in combination with the
minor alleles of the two APOA5 SNPs can result in
greater susceptibility to elevation of the TG:HDL-C ratio
and MS risk (Tables 2 and 3). In contrast, in men, the
minor alleles of the two SNPs located in the APOA5 locus
(rs662799 and rs651821), rather than the rs6589566 allele,
will produce the dominant effects. In other words, sex-
dependent association of the APOA5 SNPs with the TG:
HDL-C ratio and MS risk can be determined by using
haplotype analyses of the SNPs in the APOA5–ZNF259
locus. These gender effects are different from those previ-
ously reported [11], although we also found greater sus-
ceptibility to MS with the presence of the ht2 haplotype in
men than in women (Table 3), which is similar to the pre-
viously reported gender effect of the APOA5*2 haplotype
on MS risk [11].
In a study involving haplotype analysis of a 150-kb re-
gion spanning the apolipoprotein gene cluster (APOA1–
C3–A4–A5), the SNPs in ZNF259 were separated from
those in the APOA5 haplotype block [6]. However, in this
haplotype analysis, rs1942478 and rs603446 in the
ZNF259 intron, were weakly correlated with rs6589566,
which is in strong LD with APOA5 SNPs: r2 = 0.125 for
rs1942478 and r2 = 0.164 for rs603446 in the Chinese
HapMap population [6]. Therefore, the APOA5 haplotype
block can be extended to the ZNF259 gene region using
rs6589566 and rs964184 located in the ZNF259 intron.
The most obvious weakness of our study is that it is
cross-sectional; thus, it would be necessary to confirm
the sex-dependent effects of the APOA5–ZNF259 haplo-
types on cardiometabolic risk via longitudinal analyses.
Although haplotype ht3 and the TG:HDL-C ratio appear
to function in identifying cardiometabolic risk, we can-
not conclude that the TG:HDL-C ratio will be as effect-
ive in predicting clinical outcomes as a diagnosis of MS.
However, despite these weaknesses, the simplicity of the
TG:HDL-C ratio approach has obvious advantages: the
TG:HDL-C ratio, which relies on two commonly used
laboratory measurements, can provide a relatively simple
way to identify apparently healthy insulin-resistant per-
sons with increased cardiometabolic risk, since the TG:
HDL-C concentration ratio is significantly related to a dir-
ect measure of insulin-mediated glucose disposal [23-25].
Conclusions
In conclusion, we found that haplotypes formed from
three SNPs located in APOA5 and ZNF259, viz., rs662799,rs651821, and rs6589566, were significantly associated
with susceptibility to MS and elevation of the log[TG]:
HDL-C ratio, sex-dependently, in Koreans; in particular,
the ht3 haplotype was associated with these traits in
women. We believe that our findings will help to further
develop the clinical utility of the APOA5 haplotypes and




All subjects provided written informed consent to par-
ticipate in the study, and the study was approved by the
Institutional Review Board of the Korea Institute of
Oriental Medicine.
We recruited 2,949 subjects from 22 oriental medical
clinics who were a part of the Korea Constitution Multi-
center Study for 6 years since 2006 [1,26]. This popula-
tion contained 690 patients who had hypertension,
dyslipidemia, and/or diabetes. None of the subjects had
a history of cancer treatment, thyroid dysfunction, or
postmenopausal hormonal therapy. The subjects with
MS were defined according to the modified guidelines of
National Cholesterol Education Program Adult Treat-
ment Panel III (NCEP ATP III) [27], which stipulated
that at least three of the following five criteria had to be
met: (1) abdominal obesity with waist circumference ≥
90 cm for men and ≥ 80 cm for women [28], (2) systolic
blood pressure ≥ 130 mmHg, diastolic blood pressure ≥
85 mmHg, or medication for hypertension, (3) TG ≥
150 mg/dL, (4) HDL-C < 40 mg/dL for men and < 50 mg/
dL for women, and (5) fasting blood glucose ≥ 110 mg/dL
or medication for hyperglycemia.
Genotyping of SNPs
Since TG-elevating and HDL-C-lowering SNPs in APOA5
and ZNF259 (rs662799, rs651821, rs2072560, rs2266788,
rs6589566, and rs964184) are strongly correlated with
each other in Asian HapMap population (r2 > 0.8), we se-
lected three SNPs across the two genes, viz., rs662799
(−1131 of APOA5; one of representative SNPs for
APOA5*2 haplotype), rs651821 (−3 of APOA5; a coding
SNP in the 5′ untranslated region and one of the repre-
sentative SNPs for APOA5*2 haplotype), and rs6589566 (a
SNP in ZNF259 intron 12). For example, rs6589566 was
strongly linked both with rs964184 (D′ = 0.98, r2 = 0.97 in
Asian HapMap population) and with rs2266788 (D′ = 1.0,
r2 = 0.98 in Asian HapMap population). The rs3135506
was not selected as a representative SNP for APOA5*3
haplotype, as it is monomorphic in Asian populations.
The genotypes of the three SNPs were determined
using two genotyping methods, by using the Affymetrix
Genome-Wide Human SNP array 5.0 (Affymetrix, Santa
Clara, CA) and unlabeled oligonucleotide probes (UOPs)
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trix SNP array 5.0 was used for rs6589566 in 882 sub-
jects [30], and the UOP genotyping method was used for
the three SNPs (in the rest of the 2,067 subjects for
rs6589566). The details of the genotyping method using
UOPs (oligonucleotide sequences: Additional file 2) have
been described in a previous report [1].
Statistical analysis
The chi-squared test was used to determine whether the
SNPs deviated from Hardy–Weinberg equilibrium in
studied population. LD (Lewontin’s D′ = D/|Dmax| and
r2) was obtained from Haploview program, version 4.2
(Daly Lab at the Broad Institute, Cambridge, MA) [31].
Construction of haplotypes of APOA5 SNPs was imple-
mented with Phase, version 2.1, which is a Bayesian
algorithm-based program [32,33]. Multiple linear regres-
sion analyses were performed for a ratio of log[TG] to
HDL-C, after adjusting for age, sex, physical activity
(three categories), daily food intake (three categories),
clinical history of hypertension, dyslipidemia, and/or dia-
betes, and medications for the three diseases. Multiple
logistic regression analyses with the same adjustments,
except medications, used in the multiple linear regres-
sions were used for determining the effects of SNPs on
MS risk. The p-values of < 0.05 were considered signifi-
cant. All statistical analyses were performed using R, ver-
sion 2.15.2 (http://www.r-project.org/).
Additional files
Additional file 1: Characteristics of the subjects with MS and
control subjects.
Additional file 2: The oligonucleotide sequences of primers and
UOPs for 3 SNPs of APOA5 genotyped in Koreans.
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